News
23. August 2007
SymbioTec has initiated the procedure for obtaining the designation as Orphan Medicinal Product in Europe for its drug ONCOHIST for the treatment of AML (acute myeloid leukaemia). The pre-submission meeting with EMEA (The European Agency for the Evaluation of Medicinal Products) was very encouraging.
News Archive
7. January 2008: SymbioTec has initiated the procedure for obtaining the design...23. August 2007: SymbioTec has initiated the procedure for obtaining the design...
Downloads
Poster Freiburg September 2007 (9.4 KB)Poster ASH Meeting December 2007 (12.4 KB)
Poster Pharma Forum 2005 (PDF) (95.7 KB)
Press Release Feb 2005 (PDF) (9.5 KB)
